GeneFerm Biotechnology , Ltd. Accounts Payable

The latest accounts payable for 1796.TWO is $28M as of June 2026. That compares with $22M in the prior-year period — up 31.4% year over year. Investors often review this figure alongside GeneFerm Biotechnology , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 1796.TWO's accounts payable moved from $22M to $28M — a 31.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in GeneFerm Biotechnology , Ltd.'s operating scale or balance-sheet position.

A accounts payable figure of $28M for 1796.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 1796.TWO's accounts payable ($28M), review year-over-year change from $22M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.